Umit Tapan, MD
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Hematology & Medical Oncology

MD, Hacettepe University



Dr. Umit Tapan is an Assistant Professor of Medicine at Chobanian and Avedisian School of Medicine and practicing Thoracic Oncologist at Boston Medical Center. His clinical interests are Non-small cell lung cancer, Small cell lung cancer, Mesothelioma, Immunotherapy, Targeted therapy/Precision Medicine. His research interests include Circulating tumor DNA, Gut microbiome and Cancer Immunotherapy, Racial Disparities in Cancer Care and Outcomes.

Dr. Tapan completed his fellowship in Hematology & Oncology at Boston Univesity Medical Center, in which he was Chief Fellow in Hematology & Oncology. Dr. Tapan completed his internship and residency at Steward Carney Hospital. He earned his medical degree from Hacettepe University School of Medicine, Ankara, Turkey.

Diversity, Equity, Inclusion and Accessibility

I am honored to be working with my colleagues in providing exceptional care without exception. I have dedicated my research efforts to improving access to state-of-the art testing (also called "molecular profiling") and innovative treatments (including immunotherapy and personalized medicine) in lung cancer patients. I am an international medical graduate and I have been welcomed by the multicultural environment in the United States since my arrival in 2009. I strive to improve my understanding of the diverse cultures and backgrounds, in healthcare and in the society at large. Furthering the efforts to reduce disparities in lung cancer care, I have joined a National Thoracic Cancer Clinical Trial Working Group, with the goal of increasing enrollment of diverse patient populations to the clinical trials.

Member
Boston University
BU-BMC Cancer Center


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research





SGN-B6A: A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer
11/07/2024 - 11/07/2031 (PI)
Seattle Genetics, Inc.

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated L
04/04/2025 - 04/03/2030 (PI)
Janssen Research and Development, LLC

SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression =5
05/06/2024 - 05/05/2027 (PI)
Lilly USA, LLC


A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
12/15/2023 - 12/14/2026 (PI)
Janssen Research and Development, LLC


ML41591 NAUTIKA 1
10/25/2023 - 10/24/2026 (PI)
Genentech, Inc.


Janssen 73841937NSC1001: An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody i
02/12/2021 - 09/30/2026 (PI)
Janssen Research and Development, LLC


GSK213824
07/20/2023 - 07/19/2026 (PI)
GlaxoSmithKline


MK-7684A-006-00
07/06/2023 - 07/05/2026 (PI)
Merck


LCMC LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers
01/22/2024 - 01/21/2026 (PI)
Lung Cancer Research Foundation


SKY06/ BO42592:A Phase II/III, Randomized, Double-blind, Placebo-controlled Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients with Pre
09/29/2022 - 09/28/2025 (PI)
Genentech, Inc.


Showing 10 of 12 results. Show All Results

Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Shah MV, Solem CT, Bell KF, Aziez A, Sun X, Du M, Du EX, Yang H, Wang H, Hua Q, Tapan U. Real-World Maintenance Treatment Patterns Among Patients with Advanced Non-Small Cell Lung Cancer. Adv Ther. 2025 Jun; 42(6):2782-2796. PMID: 40232624
     
  2. Radwan A, Jani CT, Al Omari O, Patel M, Burns L, Mackay Z, Li L, Mahdaviani K, Davidson A, Weinberg J, Everett PC, Suzuki K, Mak KS, Kulke MH, Tapan U. The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients. Oncologist. 2025 Mar 10; 30(3).View Related Profiles. PMID: 39603266; PMCID: PMC11954504; DOI: 10.1093/oncolo/oyae279;
     
  3. Murphy JF, Amin LB, Celikkaleli ST, Brown HE, Tapan U. Disparities in cancer care in individuals with severe mental illness: A narrative review. Cancer Epidemiol. 2024 Dec; 93:102663. PMID: 39255550
     
  4. Burns L, Tukachinsky H, Raskina K, Huang RSP, Schrock AB, Sands J, Kulke MH, Oxnard GR, Tapan U. Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma. Lung Cancer. 2024 Feb; 188:107454.View Related Profiles. PMID: 38159439
     
  5. Dudipala H, Burns L, Jani CT, Radwan A, Al Omari O, Patel M, Kilic S, Zhao J, Mak K, Suzuki K, Tapan U. Disparities in Lung Cancer Clinical Trial Discussion and Enrollment at a Safety Net Hospital. Community Health Equity Res Policy. 2023 Dec 12; 2752535X231221394.View Related Profiles. PMID: 38087807
     
  6. Burns L, Hsu CY, Whisenant JG, Marmarelis ME, Presley CJ, Reckamp KL, Khan H, Jo Fidler M, Bestvina CM, Brahmer J, Puri S, Patel JD, Halmos B, Hirsch FR, Liu SV, Costa DB, Goldberg SB, Feldman LE, Mamdani H, Puc M, Mansfield AS, Islam N, Scilla KA, Garassino MC, Horn L, Peters S, Wakelee HA, Charlot M, Tapan U. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT). Lung Cancer. 2023 Dec; 186:107423.View Related Profiles. PMID: 37995456
     
  7. Kilic S, Zhao J, Okut H, Jani CT, Radwan A, Dudipala H, Burns L, Tapan U. Disparities in US Lung Cancer Clinical Trial Enrollment. J Racial Ethn Health Disparities. 2024 Oct; 11(5):3201-3209.View Related Profiles. PMID: 37651069
     
  8. Al Omari O, Jani C, Ahmed A, Singh H, Radwan A, Bhatt P, Walker A, Agarwal L, Goodall R, Shalhoub J, Marshall DC, Thomson CC, Salciccioli JD, Tapan U. Lung Cancer Mortality in the United States between 1999 and 2019: An Observational Analysis of Disparities by Sex and Race. Ann Am Thorac Soc. 2023 Apr; 20(4):612-616. PMID: 36476451; PMCID: PMC10112410; DOI: 10.1513/AnnalsATS.202206-510RL;
     
  9. Qureshi MM, Kam A, Suzuki K, Litle V, Tapan U, Balasubramaniyan R, Dyer MA, Truong MT, Mak KS. Association between hospital safety-net burden and receipt of trimodality therapy and survival for patients with esophageal cancer. Surgery. 2023 May; 173(5):1153-1161.View Related Profiles. PMID: 36774317
     
  10. Siddiqi N, Pan G, Liu A, Lin Y, Jenkins K, Zhao J, Mak K, Tapan U, Suzuki K. Timeliness of Lung Cancer Care From the Point of Suspicious Image at an Urban Safety Net Hospital. Clin Lung Cancer. 2023 Mar; 24(2):e87-e93.View Related Profiles. PMID: 36642641
     
Showing 10 of 37 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 37 publications over 16 distinct years, with a maximum of 6 publications in 2022 and 2023

YearPublications
20082
20091
20101
20112
20122
20145
20153
20161
20171
20181
20201
20212
20226
20236
20241
20252


Expanding Access to NSCLC Innovations: Challenges and Opportunities

AJMC 10/18/2024

?Racial, Socioeconomic Disparities in Extensive-Stage Small Cell Lung Cancer Treatment

Oncology Times 2/9/2022

Black Americans Don’t Get Screened or Treated for Lung Cancer at Same Rates as White Americans: Here’s Why, & What We Can Do About It

Survivor Net 2/16/2021

Racial and Other Disparities Persist Among Patients with Extensive-Stage Small Cell Lung Cancer

Cure Today 11/16/2020

Study Finds Racial and Socioeconomic Disparities in Chemo Treatment for ES-SCLC

Cancer Network 11/2/2020

Quality Data, Genetic Testing Can Reduce Cancer Care Disparities

Health IT Analytics 10/27/2020

US healthcare: Black people less likely to receive lung cancer chemotherapy

Open Access News 10/27/2020
Contact for Mentoring:

617.638.7523
Download vCard

Tapan's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (183) concept(s)
_
Media Mentions
_
Co-Authors
See all (32) people
_
Similar People
See all (60) people
_
Same Department
Search Department